ZANIDATAMAB
Product
JAZZ PHARMACEUTICALS INC.
Total Payments
$101,911
Transactions
89
Doctors
21
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $101,911 | 89 | 21 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $91,660 | 17 | 89.9% |
| Travel and Lodging | $7,021 | 28 | 6.9% |
| Food and Beverage | $3,230 | 44 | 3.2% |
Top Doctors Receiving Payments for ZANIDATAMAB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Medical Oncology | Scottsdale, AZ | $12,315 | 10 |
| , MD | Hematology & Oncology | Houston, TX | $11,900 | 2 |
| , MD | Anatomic Pathology | Saint Louis, MO | $11,531 | 14 |
| , MD | Hematology & Oncology | Houston, TX | $11,455 | 11 |
| , MD | Hematology & Oncology | New York, NY | $10,506 | 12 |
| , MD | Internal Medicine | Houston, TX | $7,668 | 11 |
| , MD | Internal Medicine | Houston, TX | $7,500 | 1 |
| , M.D., PH.D | Anatomic Pathology | New York, NY | $6,750 | 1 |
| , MD | Medical Oncology | Dallas, TX | $6,130 | 8 |
| Aatur Singhi | Anatomic Pathology & Clinical Pathology | Baltimore, MD | $3,375 | 1 |
| , MD | Medical Oncology | New York, NY | $3,240 | 1 |
| , MD | Medical Oncology | Tyler, TX | $2,790 | 1 |
| , MD | Hematology & Oncology | Cookeville, TN | $2,760 | 1 |
| , M.D., PH.D | Internal Medicine | New York, NY | $2,435 | 4 |
| , CRNP | Acute Care | Baltimore, MD | $900.00 | 1 |
| , M.D | Hematology & Oncology | Nashville, TN | $145.62 | 1 |
| , MD | Medical Oncology | Houston, TX | $145.62 | 1 |
| , MD, MPH | Medical Oncology | Tampa, FL | $145.62 | 1 |
| , MD | Hematology & Oncology | Cleveland, OH | $94.62 | 3 |
| , MD | Medical Oncology | Kansas City, MO | $94.62 | 3 |
| , MD | Internal Medicine | Seattle, WA | $29.67 | 1 |
Ad
Manufacturing Companies
- JAZZ PHARMACEUTICALS INC. $54,501
- Jazz Pharmaceuticals Inc. $47,410
Product Information
- Type Product
- Total Payments $101,911
- Total Doctors 21
- Transactions 89
About ZANIDATAMAB
ZANIDATAMAB is a product associated with $101,911 in payments to 21 healthcare providers, recorded across 89 transactions in the CMS Open Payments database. The primary manufacturer is JAZZ PHARMACEUTICALS INC..
Payment data is available from 2023 to 2023. In 2023, $101,911 was paid across 89 transactions to 21 doctors.
The most common payment nature for ZANIDATAMAB is "Consulting Fee" ($91,660, 89.9% of total).